Literature DB >> 16474148

Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients.

Søren U Nielsen1, Margaret F Bassendine, Alastair D Burt, Caroline Martin, Wanna Pumeechockchai, Geoffrey L Toms.   

Abstract

Hepatitis C virus (HCV) RNA circulates in the blood of persistently infected patients in lipoviroparticles (LVPs), which are heterogeneous in density and associated with host lipoproteins and antibodies. The variability and lability of these virus-host complexes on fractionation has hindered our understanding of the structure of LVP and determination of the physicochemical properties of the HCV virion. In this study, HCV from an antibody-negative immunodeficient patient was analyzed using three fractionation techniques, NaBr gradients, isotonic iodixanol, and sucrose gradient centrifugation. Iodixanol gradients were shown to best preserve host lipoprotein-virus complexes, and all HCV RNA was found at densities below 1.13 g/ml, with the majority at low density, < or =1.08 g/ml. Immunoprecipitation with polyclonal antibodies against human ApoB and ApoE precipitated 91.8% and 95.0% of HCV with low density, respectively, suggesting that host lipoprotein is closely associated with HCV in a particle resembling VLDL. Immunoprecipitation with antibodies against glycoprotein E2 precipitated 25% of HCV with low density, providing evidence for the presence of E2 in LVPs. Treatment of serum with 0.5% deoxycholic acid in the absence of salt produced HCV with a density of 1.12 g/ml and a sedimentation coefficient of 215S. The diameters of these particles were calculated as 54 nm. Treatment of serum with 0.18% NP-40 produced HCV with a density of 1.18 g/ml, a sedimentation coefficient of 180S, and a diameter of 42 nm. Immunoprecipitation analysis showed that ApoB remained associated with HCV after treatment of serum with deoxycholic acid or NP-40, whereas ApoE was removed from HCV with these detergents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16474148      PMCID: PMC1395398          DOI: 10.1128/JVI.80.5.2418-2428.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Identification of hepatitis C virus by immunoelectron microscopy.

Authors:  X Li; L J Jeffers; L Shao; K R Reddy; M de Medina; J Scheffel; B Moore; E R Schiff
Journal:  J Viral Hepat       Date:  1995       Impact factor: 3.728

2.  Low density lipoprotein receptor as a candidate receptor for hepatitis C virus.

Authors:  M Monazahian; I Böhme; S Bonk; A Koch; C Scholz; S Grethe; R Thomssen
Journal:  J Med Virol       Date:  1999-03       Impact factor: 2.327

3.  Immunochemical and biomolecular studies of circulating immune complexes isolated from patients with acute and chronic hepatitis C virus infection.

Authors:  D Sansonno; A R Iacobelli; V Cornacchiulo; G Lauletta; M A Distasi; P Gatti; F Dammacco
Journal:  Eur J Clin Invest       Date:  1996-06       Impact factor: 4.686

4.  Ultrastructural and physicochemical characterization of the hepatitis C virus recovered from the serum of an agammaglobulinemic patient.

Authors:  A Trestard; Y Bacq; L Buzelay; F Dubois; F Barin; A Goudeau; P Roingeard
Journal:  Arch Virol       Date:  1998       Impact factor: 2.574

5.  Density analysis of hepatitis C virus particle population in the circulation of infected hosts: implications for virus neutralization or persistence.

Authors:  T Kanto; N Hayashi; T Takehara; H Hagiwara; E Mita; M Naito; A Kasahara; H Fusamoto; T Kamada
Journal:  J Hepatol       Date:  1995-04       Impact factor: 25.083

6.  Murine antibodies against E2 and hypervariable region 1 cross-reactively capture hepatitis C virus.

Authors:  M Esumi; M Ahmed; Y H Zhou; H Takahashi; T Shikata
Journal:  Virology       Date:  1998-11-10       Impact factor: 3.616

7.  The physical state of the negative strand of hepatitis C virus RNA in serum of patients with chronic hepatitis C.

Authors:  M Shindo; A M Di Bisceglie; T Akatsuka; T L Fong; L Scaglione; M Donets; J H Hoofnagle; S M Feinstone
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

8.  Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins.

Authors:  A M Prince; T Huima-Byron; T S Parker; D M Levine
Journal:  J Viral Hepat       Date:  1996-01       Impact factor: 3.728

9.  Serial density analysis of hepatitis C virus particle populations in chronic hepatitis C patients treated with interferon-alpha.

Authors:  T Kanto; N Hayashi; T Takehara; H Hagiwara; E Mita; M Oshita; K Katayama; A Kasahara; H Fusamoto; T Kamada
Journal:  J Med Virol       Date:  1995-07       Impact factor: 2.327

10.  Physicochemical properties of iodixanol.

Authors:  K Eivindvik; C E Sjogren
Journal:  Acta Radiol Suppl       Date:  1995
View more
  153 in total

Review 1.  Hepatitis C virus: assembly and release of virus particles.

Authors:  Daniel M Jones; John McLauchlan
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

2.  Exiting from uncharted territory: hepatitis C virus assembles in mouse cell lines.

Authors:  Margaret A Scull; Alexander Ploss
Journal:  Hepatology       Date:  2012-02       Impact factor: 17.425

3.  Rotaviruses associate with cellular lipid droplet components to replicate in viroplasms, and compounds disrupting or blocking lipid droplets inhibit viroplasm formation and viral replication.

Authors:  Winsome Cheung; Michael Gill; Alessandro Esposito; Clemens F Kaminski; Nathalie Courousse; Serge Chwetzoff; Germain Trugnan; Nandita Keshavan; Andrew Lever; Ulrich Desselberger
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

4.  Protein kinase D negatively regulates hepatitis C virus secretion through phosphorylation of oxysterol-binding protein and ceramide transfer protein.

Authors:  Yutaka Amako; Gulam H Syed; Aleem Siddiqui
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

Review 5.  Unique ties between hepatitis C virus replication and intracellular lipids.

Authors:  Eva Herker; Melanie Ott
Journal:  Trends Endocrinol Metab       Date:  2011-04-15       Impact factor: 12.015

Review 6.  Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio De Vincentis; Giovanni Galati; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

7.  The Serum Very-Low-Density Lipoprotein Serves as a Restriction Factor against Hepatitis C Virus Infection.

Authors:  Jian Tao; Kyung-Don Kang; Stacy D Hall; Audra H Laube; Jia Liu; Matthew B Renfrow; Jan Novak; Guangxiang Luo
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

8.  Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C.

Authors:  Javier Bartolomé; Juan Manuel López-Alcorocho; Inmaculada Castillo; Elena Rodríguez-Iñigo; Juan Antonio Quiroga; Ricardo Palacios; Vicente Carreño
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

9.  Apolipoprotein c1 association with hepatitis C virus.

Authors:  Jean-Christophe Meunier; Rodney S Russell; Ronald E Engle; Kristina N Faulk; Robert H Purcell; Suzanne U Emerson
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

10.  Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells.

Authors:  Baptiste Jammart; Maud Michelet; Eve-Isabelle Pécheur; Romain Parent; Birke Bartosch; Fabien Zoulim; David Durantel
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.